PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 30 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Total flavonoids of Desmodium styracifolium (TFDS) were evaluated for effectiveness in removing residual stones following flexible ureteroscopic lithotripsy [PMID:39664792]
Total flavonoids (TFDS) attenuated the formation of calcium oxalate stones in rats [PMID:28567512]. Triterpenoids reduced the incidence of stone formation from 81% to 29% in rats [PMID:8461944].
Total flavonoids (TFDS) showed renoprotective properties by suppressing ferroptosis [PMID:41065914]
Evidence summary
PubMed sources
- 1.PMID: 39454708 (2025) — Desmodium styracifolium (Osb.) Merr. Extracts alleviate cholestatic liver disease by FXR pathway. · Journal of ethnopharmacology
- 2.PMID: 38317880 (2024) — Desmodium styracifolium: Botanical and ethnopharmacological insights, phytochemical investigations, and prospects in pharmacology and pharmacotherapy. · Heliyon
- 3.PMID: 38646844 (2024) — Carboxymethylated Desmodium styracifolium polysaccharide reduces the risk of calcium oxalate kidney stone formation by inhibiting crystal adhesion and promoting crystal endocytosis. · Journal of cellular physiology
- 4.PMID: 40897849 (2025) — Therapeutic potential of Desmodium styracifolium polysaccharide in attenuating nano-calcium oxalate induced renal injury and fibrosis. · Communications biology
- 5.PMID: 35342799